Selodenoson

Drug Profile

Selodenoson

Alternative Names: DT-009; DTI 0009; RG 14202

Latest Information Update: 18 Aug 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aderis Pharmaceuticals (CEASED)
  • Class Antiarrhythmics
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Supraventricular arrhythmias

Most Recent Events

  • 01 Jun 2005 As a result of corporate merger activities Aderis Pharmaceuticals has ceased operations
  • 22 Mar 2005 Data presented at the 106th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2005) have been added to the Arrhythmias pharmacodynamics section
  • 30 Jul 2004 Fujisawa has terminated its licence for selodenoson in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top